Lytenava, from Outlook Therapeutics, is set to become the first ophthalmic formulation of bevacizumab to be approved in the EU, after the European Medicines Agency this week recommended in favor of using the VEGF inhibitor to treat wet age-related macular degeneration (wet AMD).
If it is authorized by the European Commission, Outlook believes the intravitreally injected product would provide a less expensive alternative...






